A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months

CompletedOBSERVATIONAL
Enrollment

402

Participants

Timeline

Start Date

September 16, 2013

Primary Completion Date

July 13, 2018

Study Completion Date

July 13, 2018

Conditions
Deep Infiltrating Endometriosis (DIE)
Interventions
DRUG

Triptorelin Acetate 3.75mg intramuscular injection

"Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks."

Trial Locations (18)

100029

Beijing Anzhen Hospital,Capital Medical University, Beijing

100044

Peking University People's Hospital, Beijing

100096

Beijing Jishuitan Hospital, Beijing

100853

Chinese PLA General Hospital, Beijing

200011

Obstetrics and Gynecology Hospital of Fudan University, Shanghai

200030

The International Peace Maternity & Child Health Hospital of China, Shanghai

201204

Shanghai First Maternity and Infant Hospital, Shanghai

210011

Nanjing Maternity and Child Health Care Hospital, Nanjing

230031

Anhui Provincial Cancer Hospital,Hefei,China,230031, Hefei

310006

Women's Hospital, School of Medicine, Zhejiang University, Hangzhou

330008

Jiangxi Maternal and Child Health Hospital,Nanchang, Nanchang

400037

Xinqiao Hospital,Third Military Medical University, Chongqing

400038

Southwest Hospital,Chongqing,400038, Chongqing

430022

Huazhong University of Science and Technology, Wuhan

430060

Renmin Hospital of Wuhan University (Hubei General Hospital), Wuhan

450008

Henan Provincial People's Hospital, Zhengzhou

518020

Shenzhen People's Hospital, Shenzhen

030001

The Second Hospital of Shanxi Medical University,Taiyuan, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY